# CereVasc

> CereVasc is a Boston clinical-stage medical device company developing the investigational eShunt System, a catheter-delivered implant that drains cerebrospinal fluid into the venous system to treat communicating hydrocephalus. It completed STRIDE pivotal-trial enrollment in June 2026 and is preparing for potential commercialization, subject to clinical results and regulatory approval.

- **Founded:** 2014
- **Headquarters:** Boston, United States
- **Founders:** Carl Heilman (Co-founder; neurosurgeon and eShunt co-inventor), Adel Malek (Co-founder and Chief Medical Officer)
- **Products:** eShunt System, Follow-on CNS therapy delivery concepts
- **Notable:** First patient treatment announced in February 2021., Co-founders received the 2022 SVIN Innovation Award., FDA Breakthrough Device Designation for adult NPH in 2024 and communicating hydrocephalus in pediatric patients aged 12 and older in April 2025.

## Products & services

- **eShunt System** — Investigational endovascular cerebrospinal fluid shunt and delivery components for communicating hydrocephalus, including normal pressure hydrocephalus; not approved for commercial sale.
- **Follow-on CNS therapy delivery concepts** — Research-stage concepts using endovascular access for delivery of central nervous system therapies; CereVasc seeks pharmaceutical and biotechnology collaborators.

## Achievements

- First patient treatment announced in February 2021.
- Co-founders received the 2022 SVIN Innovation Award.
- FDA Breakthrough Device Designation for adult NPH in 2024 and communicating hydrocephalus in pediatric patients aged 12 and older in April 2025.
- Completed STRIDE enrollment at 32 clinical sites in June 2026.
- Opened Wilmington manufacturing and research facility with ISO Class 7 clean room in July 2026.
- Reported more than 200 patients treated worldwide in September 2026.

## Latest updates

- **2026-09** — Tony Kingsley appointed President and CEO effective September 15; Dan Levangie transitioned to Chairman.
- **2026-07** — Opened manufacturing and research facility at 200 Ballardvale Street in Wilmington, Massachusetts.
- **2026-06** — Completed STRIDE enrollment at 32 sites; follow-up and regulatory work continue.
- **2026-06** — Announced initial closing of $85 million Series C.
- **2026-02** — Announced publication of 66-patient, 90-day NPH study; the paper reports no device-related serious adverse events and two procedure-related serious adverse events.

## Links

- Website: https://cerevasc.com/
- LinkedIn: https://www.linkedin.com/company/cerevasc
- Instagram: https://www.instagram.com/cerevasc/

---

Profile page: https://yespress.io/cerevasc
Published by YesPress — https://yespress.io
Last updated: 2026-10-03